Response to Dr. Mahan Regarding Key Points to Consider When Evaluating Andexxa for Formulary Addition
Crossref DOI link: https://doi.org/10.1007/s12028-020-01007-0
Published Online: 2020-06-03
Published Print: 2020-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Peled, Harry http://orcid.org/0000-0003-0016-3574
Dau, Nhu Quyen
Lau, Helen
Text and Data Mining valid from 2020-06-03
Version of Record valid from 2020-06-03
Article History
First Online: 3 June 2020
Conflicts of interest
: The authors declare that they have no conflicts of interest.